At the St. Gallen Conference 2017, the panel was inconclusive about the use of bisphosphonates during adjuvant endocrine therapy to improve disease-free survival – irrespectively of bone mineral density – in premenopausal patients on ovarian function suppression therapy (plus tamoxifen or aromatase inhibitor) (53% yes, 37% no, 10% abstain). Now, 2 years later, there was still no consensus; the panellists voted in exactly the same way. However, the support for the use of bisphosphonates during endocrine therapy to improve disease-free survival in postmenopausal patients has increased: 2 years ago, 76% of the panellists endorsed the use of bisphosphonates for these patients while this year 84% of the panellists was in favour of the therapy. Remarkably, when asked whether the panellists prescribe bisphosphonates in their own daily practice, like they just recommended, only 43% of the panellists voted for “yes” (40% voted “no”, 17% abstained). The opinion of the panellists on the use of denosumab (60 mg twice a year) instead of bisphosphonates was crystal clear, however: 75% of the panellists were not in favour of the use of denosumab, echoing the results of the recently presented data of the D-CARE trial .
- Coleman RE, et al. J Clin Oncol 2018; 36 (supp) abstract 105.
Table of Contents: BCC 2019
St. Gallen Consensus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.